GOG 0218 PDF

GOG 0218 PDF

GOG randomized, double-blind, placebo-controlled phase III trial: (A) study design; (B) progression-free survival analysis (reproduced with permission) Download scientific diagram | Design of Study GOG from publication: Time for a Level Playing Field: Inequalities in Regulatory/Approval Processes–The. ASCO Annual Meeting CHICAGO — The addition of bevacizumab as maintenance therapy to first-line treatment with standard.

Author: Brale Mulkis
Country: Cayman Islands
Language: English (Spanish)
Genre: Science
Published (Last): 13 June 2006
Pages: 77
PDF File Size: 11.38 Mb
ePub File Size: 18.33 Mb
ISBN: 652-6-36703-681-9
Downloads: 83958
Price: Free* [*Free Regsitration Required]
Uploader: Fenos

Upon completion of indicated cycles of combination therapy, Avastin is indicated for continued use as a single agent until disease progression in patients with platinum-sensitive recurrent ovarian cancer.

Efficacy data overview in ITT population [ 1 ]. Efficacy data overview [ 1 ].

Avastin® (bevacizumab) Efficacy | Stage III or IV Ovarian Cancer & psOC, prOC

Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites. The GOG study included a diverse population of women [ 1 ]. Study design and patient population [ 1,54 ]. Metastatic renal cell carcinoma mRCC Avastin, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma.

Persistent, recurrent, or metastatic cervical cancer CC Avastin, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the 0281 of patients with persistent, recurrent, or metastatic cervical cancer.

Summary of efficacy data from Avastin pivotal trials. Median Yog by chemotherapy cohort. Cohort analysis was exploratory.

Pregnancy warning Based on the mechanism of action and animal studies, Avastin may cause fetal harm Advise female patients that Avastin may cause fetal harm, and to inform their 00218 provider of a known or suspected pregnancy Advise females of reproductive potential to use effective contraception gg treatment with Avastin and for 6 months after the last dose of Avastin Advise nursing women that breastfeeding is not recommended during treatment with Avastin and for 6 months following their last dose of treatment Avastin may impair fertility.

  AWWA C207 07 PDF

Bevacizumab Approved by FDA to Treat Ovarian Cancer Following Surgery

In patients receiving Avastin with lomustine, the adverse reaction profile was similar to that observed in other approved indications. Do not administer Avastin for at least 28 ggo after surgery and until the wound is fully healed Discontinue in patients with wound healing complications requiring medical intervention Hemorrhage Severe or fatal hemorrhage, including hemoptysis, GI bleeding, hematemesis, central nervous system hemorrhage, epistaxis, and vaginal bleeding, occurred up to 5-fold more frequently in patients receiving Avastin.

Analysis not designed to evaluate statistical significance between treatment arms or compare among the 3 chemotherapy cohorts. OS results in patients with psOC who have not received more than 1 prior chemotherapy regimen [ 1 ] Median overall survival OS: The link you have selected will take you away from this site to one that is not owned or controlled 028 Genentech, Inc.

Recurrent Glioblastoma GBM Avastin is indicated for the treatment of recurrent glioblastoma in adults. You may also report side effects to Genentech at Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line Avastin-containing regimen.

The safety data was consistent with the known safety profile established in first- and second-line MCRC 5. Recurrent epithelial ovarian, fallopian gkg, or primary peritoneal cancer rOC Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens.


Objective response rate ORR: Efficacy Data Recurrent Glioblastoma Studies. Genentech does not recommend and does not endorse the content on any third-party websites. Additional serious adverse events Additional serious and sometimes fatal adverse events with increased incidence in the Avastin-treated arm vs chemotherapy arm vog These data are likely to underestimate the true adverse event rates due to the reporting mechanisms used in this study.

The GOG study evaluated Avastin plus chemotherapy vs chemotherapy alone in platinum-sensitive ovarian cancer [ 1,3 ]. Median progression-free survival PFS: Efficacy data overview [1].

Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. PFS data are based on investigator assessment. Dosing and Usage Doses and Duration. Recommended dosing for approved cancer types. The glg of patients with measurable disease at baseline was in the Avastin plus chemotherapy arm and in the chemotherapy alone arm Median OS: Prescribing Information Register for Updates References.

Do not administer Avastin for at least 28 days gof surgery and until the wound is fully healed Discontinue in patients with wound healing complications requiring medical intervention Hemorrhage Severe or fatal hemorrhage have occurred Do not administer Avastin to vog with serious hemorrhage or recent history of hemoptysis Discontinue for Grade hemorrhage.